Linagliptin/Metformin Sandoz

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin)

Q: What is Linagliptin/Metformin Sandoz used for?

Linagliptin/Metformin Sandoz is prescribed for the treatment of type 2 diabetes mellitus in adults. It combines a DPP‑4 inhibitor (linagliptin) with a biguanide (metformin) to improve blood‑glucose control when used together with diet and exercise.

Q: How does linagliptin work in this combination?

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which results in higher levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping to lower blood sugar.

Q: What is the usual dose of Linagliptin/Metformin Sandoz?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Linagliptin/Metformin safe during pregnancy or breastfeeding?

Safety data for Linagliptin/Metformin in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Linagliptin/Metformin Sandoz from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Linagliptin/Metformin compare with other antidiabetic options?

Compared with metformin alone, the addition of linagliptin provides a complementary mechanism that enhances insulin secretion without causing weight gain. Unlike sulfonylureas, it has a lower risk of hypoglycemia, and unlike insulin, it is administered orally rather than by injection.

Q: What are the storage requirements for Linagliptin/Metformin Sandoz?

Store the tablets at room temperature, below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Q: How is Linagliptin/Metformin administered?

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Q: What are the most serious risks associated with Linagliptin/Metformin?

The most serious risks include lactic acidosis (especially in patients with renal impairment), acute pancreatitis, severe hypersensitivity reactions, and significant renal or hepatic dysfunction. Patients should be educated to seek immediate medical attention if they experience symptoms such as persistent vomiting, abdominal pain, or signs of an allergic reaction.

Q: Who should not use Linagliptin/Metformin Sandoz?

The combination should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis. It is also contraindicated in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.

Linagliptin and Metformin Hydrochloride, the active ingredients in Linagliptin/Metformin Sandoz, are a DPP‑4 inhibitor and a biguanide presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients.

GNH India supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU GMP standards and offers flexible order volumes to meet the needs of diverse healthcare providers.

Manufacturer / TM Owner

Sandoz Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.
Type 2 diabetes mellitus: improves glycemic control as part of a comprehensive treatment plan that includes diet and exercise.
Patients inadequately controlled on metformin alone: provides additional glucose‑lowering effect when combined with metformin.
Combination therapy with other antidiabetic agents: can be used alongside sulfonylureas, insulin, or SGLT2 inhibitors to achieve target HbA1c.

How It Works

Linagliptin selectively inhibits dipeptidyl peptidase‑4, raising endogenous incretin (GLP‑1 and GIP) levels, which enhances glucose‑dependent insulin secretion and suppresses glucagon release. Metformin hydrochloride decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity, together producing a complementary reduction in blood glucose.

Side Effects

Like all antidiabetic agents, Linagliptin/Metformin may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Nausea or upset stomach
Diarrhea or loose stools
Headache
Dizziness
Mild hypoglycemia when used with sulfonylureas or insulin
Metallic taste

Serious or Rare Side Effects

Lactic acidosis (especially in renal impairment)
Acute pancreatitis
Severe hypersensitivity reactions (e.g., angioedema, Stevens‑Johnson syndrome)
Hepatic failure
Significant renal function decline
Persistent vomiting or abdominal pain

Precautions & Warnings

Patients should be evaluated for renal and hepatic function before initiating therapy, and monitored regularly during treatment.
Renal function monitoring: assess eGFR before starting and periodically thereafter.
Hepatic function monitoring: check liver enzymes at baseline and as clinically indicated.
Risk of lactic acidosis: avoid in patients with severe renal impairment or conditions predisposing to hypoxia.
Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited.
Drug‑interaction vigilance: review concomitant medications that may affect metformin clearance or increase hypoglycemia risk.
Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin/Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk.
Iodinated contrast agents: discontinue metformin before and after imaging to prevent accumulation.
Carbamazepine: induces metabolism, reducing linagliptin exposure.
Cimetidine: may increase metformin plasma concentrations.
Rifampicin: decreases linagliptin levels, reducing glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: increased risk of hypoglycemia; adjust dose as needed.
Diuretics (especially thiazides): may impair renal function, raising metformin levels.
ACE inhibitors/ARBs: monitor renal function and electrolytes.
NSAIDs: can affect renal clearance of metformin.
Beta‑blockers: may mask hypoglycemia symptoms.

Frequently Asked Questions

Linagliptin/Metformin Sandoz is prescribed for the treatment of type 2 diabetes mellitus in adults. It combines a DPP‑4 inhibitor (linagliptin) with a biguanide (metformin) to improve blood‑glucose control when used together with diet and exercise.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which results in higher levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping to lower blood sugar.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Linagliptin/Metformin in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of linagliptin provides a complementary mechanism that enhances insulin secretion without causing weight gain. Unlike sulfonylureas, it has a lower risk of hypoglycemia, and unlike insulin, it is administered orally rather than by injection.

Store the tablets at room temperature, below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include lactic acidosis (especially in patients with renal impairment), acute pancreatitis, severe hypersensitivity reactions, and significant renal or hepatic dysfunction. Patients should be educated to seek immediate medical attention if they experience symptoms such as persistent vomiting, abdominal pain, or signs of an allergic reaction.

The combination should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis. It is also contraindicated in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.